Entries by

Inter-laboratory ring trial of the GARD™air assay for assessment of respiratory sensitizers

Andy Forreryd1, Joshua Schmidt1, Robin Gradin1, Florence Burleson, Helge Gehrke3, Henrik Johansson1. 1SenzaGen AB, Lund, Sweden. 2Burleson Research Technologies, Morrisville, NC, USA. 3Eurofins BioPharma Product Testing Munich GmbH, Planegg, Germany. Sensitization of the respiratory tract by sensitizing chemicals may lead to severe bronchoconstriction and asthma-like symptoms with a potentially fatal outcome. However, proactive identification and […]

Web-based SOT 2020 poster presentation session

Join SenzaGen’s free web-based SOT 2020 poster presentation session Don’t miss the opportunity to participate in our web-based conference on the latest news about the GARD™ assays for skin and respiratory sensitization testing. Key takeaways – Comparative study: GARDskin for challenging substances – How to test UVCBs and Mixtures – Formal validation of GARDpotency for […]

An integrated transcriptomic- and proteomic-based approach to evaluate the human skin sensitization potential of glyphosate and its commercial agrochemical formulations

Journal of Proteomics Available online 30 January 2020, 03647. https://doi.org/10.1016/j.jprot.2020.103647 Tim Lindberg, Renato Ivan de Ávila, Kathrin S. Zeller, Fredrik Levander, Dennis Eriksson, Aakash Chawaded, Malin Lindstedt Highlights Pure glyphosate was classified as a non-sensitizer using in vitro assessment. POEA, POEA+glyphosate mixture and formulations were identified as skin sensitizers. MS analysis identified protein groups related […]

GARD helps you through various challenges in your product life cycle

Here is an easy guide to how GARD skin and respiratory sensitization in vitro assays can help you through various challenges in your product life cycle. Many of our customers use our assays as an integrated part during their product development phase, for example testing for candidate ingredients, formulations or finished products, including various difficult-to-test […]

SenzaGen på Stora Aktiedagen i Stockholm

Tack alla som kom och lyssnade på VD Axel Sjöblads presentation av SenzaGens skifte från forskningsbolag till kommersiellt bolag och den pågående företrädesemissionen på Stora Aktiedagen i Stockholm den 25 november 2019. Missade du presentationen så kan du se den här: